The Food and Drug Administration has approved Lipfendra, Merck's once-daily pill for lowering LDL cholesterol, giving doctors the first oral option in a drug class that had been available only as injections.

The July 16, 2026 approval covers adults with high cholesterol, including heterozygous familial hypercholesterolemia, as an add-on to diet and exercise. The drug's generic name is enlicitide, and Merck says it will sell the 20 mg tablet under the Lipfendra brand.

The approval matters because PCSK9 drugs can sharply lower LDL, the so-called bad cholesterol linked to plaque buildup in arteries, but injectable versions have faced access, cost and prescribing barriers for years. A pill could make the class easier to discuss in routine visits, though it will still depend on insurance coverage, prescribing guidelines and patient-specific risk.

The short answer

Lipfendra is not a replacement for a cholesterol conversation with a clinician. It is a newly approved prescription medicine for adults who need additional LDL lowering, often after or alongside other lipid-lowering treatment. Patients should not stop statins or change therapy without medical guidance.

For readers, the news is less about a do-it-yourself cholesterol fix and more about a new option that may come up at future appointments. People with known heart disease, very high LDL, genetic high cholesterol or trouble reaching LDL targets are the groups most likely to hear about additional therapies, but eligibility and affordability will vary.

How it works

PCSK9 is a liver protein that limits the body's ability to clear LDL cholesterol from the blood. The FDA says Lipfendra blocks PCSK9, increasing LDL receptor activity and helping remove more LDL from circulation.

The agency based approval on two randomized, double-blind, placebo-controlled trials involving 3,207 adults. In one trial of adults with cardiovascular disease history or high risk, LDL fell 56% more than placebo at 24 weeks. In a second trial limited to adults with heterozygous familial hypercholesterolemia, LDL fell 59% more than placebo at 24 weeks.

What to check

The prescribing information says the tablet is taken once daily on an empty stomach in the morning with water, black coffee or plain tea, and patients should wait at least 30 minutes before other food or drinks. FDA and Merck also note that diarrhea and dizziness were reported more often than placebo in the HeFH trial, while discontinuation rates were similar between Lipfendra and placebo groups.

The biggest caveat is outcomes evidence. Merck says a cardiovascular outcomes trial is underway, and it is not yet known whether Lipfendra reduces cardiovascular morbidity and mortality. That does not erase the LDL-lowering approval, but it does mean the strongest claim today is about cholesterol numbers, not proven reductions in heart attacks or strokes for this specific pill.

For now, the practical takeaway is narrower: the FDA cleared a first oral PCSK9 option for LDL lowering, but individual use still turns on a clinician's assessment of risk, current treatment, side effects, cost, drug access rules and follow-up labs. Bring recent cholesterol results if asking about it.